Variants corresponding to several other liver enriched transcripts like IDH2, PROC, PKLR, ACAA1, KLKB1, ACY1, ASL, MASP2, ECI1, ADH1A, ADH1B, ADH6, HADHA, etc. are well known metabolic enzymes facilitating tumor adaptation and some of these transcripts represent potential or FDA approved drug targets. This evidence concerns the gene ADH6 and neoplasm.